This article was originally published in The Gray Sheet
Executive SummaryFirm orchestrates a $3.5 mil. round of financing through the issuance of 5% Series C convertible preferred stock. Proceeds are tabbed to support expanded marketing initiatives aimed at increasing awareness among physicians, patients and insurers of the firm's EECP (enhanced external counterpulsation) non-invasive technology for treatment of angina pectoris in patients with coronary disease. Specific programs will include patient outreach initiatives and those aimed at demonstrating to HMOs the economic benefits of the device
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.